INHIBIKASE THERAPEUTICS
Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious disease through a common mechanism of action in the host. The Company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.
INHIBIKASE THERAPEUTICS
Industry:
Health Care Health Diagnostics Therapeutics
Founded:
2008-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Website Url:
http://www.inhibikase.com
Total Employee:
51+
Status:
Active
Contact:
617-936-0184
Total Funding:
1.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics
Similar Organizations
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Board_member
2019-01-01
Current Employees Featured
Martin Joyce Chief Financial Officer @ Inhibikase Therapeutics
Chief Financial Officer
Milton Werner Founder, President & CEO @ Inhibikase Therapeutics
Founder, President & CEO
2008-08-01
Founder
Stock Details
Investors List
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Inhibikase Therapeutics
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Official Site Inspections
http://www.inhibikase.com Semrush global rank: 5.16 M Semrush visits lastest month: 1.56 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Inhibikase Therapeutics"
About :: Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics develops treatments that seek to intervene in neurodegeneration where disease begins. Our treatments flow from a novel understanding of the …See details»
Company Information :: Inhibikase Therapeutics, Inc. (IKT)
Company Contact Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway Suite 1900 Atlanta, GA 30339 T: 617-936-0184See details»
Inhibikase Therapeutics, Inc. - LinkedIn
Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify …See details»
Inhibikase Therapeutics, Inc. - AnnualReports.com
Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional …See details»
Inhibikase Therapeutics - MedPath
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related …See details»
Inhibikase Therapeutics, Inc. - Drug pipelines, Patents, Clinical ...
Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be …See details»
Inhibikase Therapeutics, Inc. Company Profile | Atlanta, GA ...
Find company research, competitor information, contact details & financial data for Inhibikase Therapeutics, Inc. of Atlanta, GA. Get the latest business insights from Dun & Bradstreet.See details»
Inhibikase Therapeutics, Inc. (IKT) - Yahoo Finance Canada
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non …See details»
Inhibikase Therapeutics - Contacts, Employees, Board Members, …
Organization. Inhibikase Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of …See details»
Inhibikase Therapeutics Announces Closing of up to …
Oct 21, 2024 Inhibikase Therapeutics-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women ...See details»
Inhibikase Therapeutics Initiates Development of Second …
Aug 21, 2023 Following submission of a request for an International Non-proprietary Name (INN) to the World Health Organization ... About Inhibikase (www.inhibikase.com) Inhibikase …See details»
Inhibikase Therapeutics — Duke OTC
Inhibikase is a clinical-stage specialty pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics for the safe and effective …See details»
Inhibikase Therapeutics Inc, IQT0:MUN profile - FT.com
Oct 31, 2024 Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. …See details»
Inhibikase Therapeutics - Funding, Financials, Valuation & Investors
Inhibikase Therapeutics is registered under the ticker NASDAQ:IKT . Their stock opened with $10.00 in its Dec 22, 2020 IPO. Stock Symbol NASDAQ:IKT ; Valuation at IPO $100.5M; …See details»
INHIBIKASE THERAPEUTICS - VentureRadar
Find out more about INHIBIKASE THERAPEUTICS, Biotech, Biotechnology and Vaccines. All; Ranked; Organisation Names; Apps and Links. Homepage (myVR) Funding Deals Hub; …See details»
Inhibikase Therapeutics Announces Expansion to its Therapeutic …
BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing …See details»
Inhibikase Therapeutics, Inc. (IKT) - Yahoo Finance Canada
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non …See details»
Inhibikase Therapeutics Secures Funding and Strengthens …
Oct 22, 2024 Inhibikase Therapeutics ( ) has shared an update. Inhibikase Therapeutics, Inc. has secured approximately $110 million through a private placement, boosting its potential …See details»
Inhibikase Therapeutics Announces Partnership with Clintrex …
Jan 4, 2021 About Inhibikase (www.inhibikase.com) ... (CLINTREX) is a clinical research organization that works with pharmaceutical and biotech companies to design clinical trials, …See details»